

107TH CONGRESS
2^D SESSION

H. R. 4832

To require the Director of the Agency for Healthcare Research and Quality to conduct studies on the comparative effectiveness and cost-effectiveness of prescription drugs that account for high levels of expenditures or use by individuals eligible for Medicare or Medicaid, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

MAY 23, 2002

Mr. ALLEN (for himself, Mr. BERRY, Mr. LANGEVIN, Mr. BROWN of Ohio, Mr. STARK, Mr. RANGEL, Ms. KAPTUR, Mr. BALDACCI, Ms. DELAURO, and Mr. WAXMAN) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To require the Director of the Agency for Healthcare Research and Quality to conduct studies on the comparative effectiveness and cost-effectiveness of prescription drugs that account for high levels of expenditures or use by individuals eligible for Medicare or Medicaid, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Prescription Drug
5 Comparative Effectiveness Act of 2002”.

1 **SEC. 2. STUDY ON EFFECTIVENESS OF CERTAIN DRUGS**
2 **USED BY INDIVIDUALS ELIGIBLE FOR MEDI-**
3 **CARE OR MEDICAID.**

4 (a) **STUDY.**—The Director of the Agency for
5 Healthcare Research and Quality shall conduct studies or
6 other analyses, which may include clinical research, to de-
7 velop or analyze valid scientific evidence regarding the
8 comparative effectiveness and cost-effectiveness of covered
9 prescription drugs relative to other drugs and treatments.

10 (b) **COVERED PRESCRIPTION DRUGS.**—For purposes
11 of this section, the term “covered prescription drugs”
12 means prescription drugs that account for high levels of
13 expenditures or use by individuals entitled to benefits
14 under the medicare or medicaid programs under titles
15 XVIII or XIX of the Social Security Act (42 U.S.C. 1395
16 et seq.; 1396 et seq.), respectively.

17 (c) **REPORT.**—Each year the Director of the Agency
18 for Healthcare Research and Quality shall—

19 (1) submit to the Congress a report on the re-
20 sults of the studies or analyses conducted under sub-
21 section (a); and

22 (2) make such report publicly available, includ-
23 ing by posting the report on the Internet.

24 (d) **AUTHORIZATION OF APPROPRIATIONS.**—There
25 are authorized to be appropriated to carry out this section

- 1 \$25,000,000 for fiscal year 2003, and such sums as may
- 2 be necessary for fiscal years thereafter.

○